Tag - Siamab Therapeutics

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. Read more >>

Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced the publication of positive preclinical data for its ST1 antibody drug conjugate (ADC) in multiple models of ovarian cancer. Siamab’s lead ST1 program targets Sialyl-Tn (STn), a tumor-associated carbohydrate antigen (TACA), which is expressed on ovarian and other solid tumors and is associated with metastatic disease, poor prognosis, chemo-resistance, and reduced overall survival. Read more >>

Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced that it will present new research findings for its ST1 monoclonal antibody (mAb) therapeutic program during a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018, being held April 14-18, 2018, at McCormick Place in Chicago. Read more >>

Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase™ 2018

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer therapeutics, today announced that Jeff Behrens, president and chief executive officer, will present at the 10th annual Biotech Showcase™ conference in San Francisco on Tuesday, January 9, 2018 at 1:45 p.m. PT. The conference will be held January 8-10, 2018, at the Hilton San Francisco Union Square. Read more >>

Boehringer Ingelheim highlights progress of immuno-oncology collaborations

In the last year, the firm has worked with the University of California at Los Angeles to develop a promising vaccine platform that can deliver a self-replicating RNA vaccine cargo to cancerous cells, helping the immune system to eliminate the cancer.
It has also partnered with Siamab Therapeutics to identify anticancer therapeutics that target tumour-associated carbohydrate antigens, while another collaboration with AbeXXa Biologics has been formed to identify new selective molecular targets for cancer from the thousands of proteins found […]

Siamab Therapeutics Presents New PreClinical Safety Data

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data demonstrating the safety of its novel anti-Sialyl-Tn (STn) antibody drug conjugates (ADCs) in multiple animal models, including non-human primates (NHPs). These results add to the company’s efficacy data findings showing that its anti-STn antibody therapeutics inhibit tumor progression in cell-line-derived and patient-derived xenograft (PDX) ovarian cancer and pancreatic cancer mouse models, with complete regression observed in some treatment arms. The preclinical […]

Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors

Siamab Therapeutics, Inc. and Boehringer Ingelheim announced today that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens (TACAs). Read more >>

Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) that show inhibition of tumor progression in in vivo and in vitro patient derived xenograft (PDX) ovarian cancer models with complete regression in some treatment arms. Read more >>